Article
Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance.
Cancer immunology research - 2 Jul 2026
Suzuki Sora, Kandar Bojidar, Ting Catrina, Deraska Peter, Chen Te-An, Giridharan Thejaswini, Khan Anm Nazmul H, Attwood Kristopher, Yu Han, Catalfamo Kayla, Singh Prashant K, Bushey Ryan T, Gottlin Elizabeth B, Campa Michael J, Patz Edward F, Ajona Daniel, Pio Ruben, Segal Brahm H, Yau Edwin H
Abstract excerpt
Loss-of-function STK11 mutations occur in 15% to 20% of lung adenocarcinomas (LUAD) and correlate with immunotherapy failure and worse survival. By integrating analysis of human tumor samples, a human LUAD cell line panel, and Cancer Cell Line Encyclopedia and The Cancer Genome Atlas datasets, we found that C3 production was increased in human STK11-mutant versus STK11-wildtype (WT) LUAD, modulated by LKB1 loss,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
